|
1
|
Huang P, Song Z and Sun X: Predictors of
anti-vascular endothelial growth factor treatment responses in
macular edema following central vein occlusion. Chin Med J (Engl).
127:3019–3023. 2014.PubMed/NCBI
|
|
2
|
Huang P, Niu W, Ni Z, Wang R and Sun X: A
meta-analysis of anti-vascular endothelial growth factor remedy for
macular edema secondary to central retinal vein occlusion. PLoS
One. 8:e824542013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McIntosh RL, Rogers SL, Lim L, Cheung N,
Wang JJ, Mitchell P, Kowalski JW, Nguyen HP and Wong TY: Natural
history of central retinal vein occlusion: An evidence-based
systematic review. Ophthalmology. 117:1113–1123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rogers SL, McIntosh RL, Lim L, Mitchell P,
Cheung N, Kowalski JW, Nguyen HP, Wang JJ and Wong TY: Natural
history of branch retinal vein occlusion: An evidence-based
systematic review. Ophthalmology. 117:1094–1101. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rogers S, McIntosh RL, Cheung N, Lim L,
Wang JJ, Mitchell P, Kowalski JW, Nguyen H and Wong TY:
International eye disease consortium: The prevalence of retinal
vein occlusion: Pooled data from population studies from the United
States, Europe, Asia and Australia. Ophthalmology. 117:313–319.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosenfeld PJ, Fung AE and Puliafito CA:
Optical coherence tomography findings after an intravitreal
injection of bevacizumab (avastin) for macular edema from central
retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 36:336–339.
2005.PubMed/NCBI
|
|
7
|
Brown DM, Campochiaro PA, Singh RP, Li Z,
Gray S, Saroj N, Rundle AC, Rubio RG and Murahashi WY; Cruise
Investigators, : Ranibizumab for macular edema following central
retinal vein occlusion: Six-month primary end point results of a
phase III study. Ophthalmology. 117:1124–1133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Demir M, Oba E, Gulkilik G, Odabasi M and
Ozdal E: Intravitreal bevacizumab for macular edema due to branch
retinal vein occlusion: 12-month results. Clin Ophthalmol.
5:745–749. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Figueroa MS, Contreras I, Noval S and
Arruabarrena C: Results of bevacizumab as the primary treatment for
retinal vein occlusions. Br J Ophthalmol. 94:1052–1056. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gallego-Pinazo R, Dolz-Marco R,
Pardo-Lopez D, Martinez-Castillo S, Lleo-Perez A, Arevalo JF and
Diaz-Llopis M: Ranibizumab for serous macular detachment in branch
retinal vein occlusions. Graefes Arch Clin Exp Ophthalmol.
251:9–14. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Prager F, Michels S, Kriechbaum K,
Georgopoulos M, Funk M, Geitzenauer W, Polak K and Schmidt-Erfurth
U: Intravitreal bevacizumab (Avastin) for macular oedema secondary
to retinal vein occlusion: 12-month results of a prospective
clinical trial. Br J Ophthalmol. 93:452–456. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Spaide RF, Chang LK, Klancnik JM, Yannuzzi
LA, Sorenson J, Slakter JS, Freund KB and Klein R: Prospective
study of intravitreal ranibizumab as a treatment for decreased
visual acuity secondary to central retinal vein occlusion. Am J
Ophthalmol. 147:298–306. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gregori NZ, Rattan GH, Rosenfeld PJ,
Puliafito CA, Feuer W, Flynn HW Jr, Berrocal AM, Al-Attar L, Dubovy
S, Smiddy WE, et al: Safety and efficacy of intravitreal
bevacizumab (avastin) for the management of branch and hemiretinal
vein occlusion. Retina. 29:913–925. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Boyd SR, Zachary I, Chakravarthy U, Allen
GJ, Wisdom GB, Cree IA, Martin JF and Hykin PG: Correlation of
increased vascular endothelial growth factor with
neovascularization and permeability in ischemic central vein
occlusion. Arch Ophthalmol. 120:1644–1650. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Campochiaro PA, Brown DM, Awh CC, Lee SY,
Gray S, Saroj N, Murahashi WY and Rubio RG: Sustained benefits from
ranibizumab for macular edema following central retinal vein
occlusion: Twelve-month outcomes of a phase III study.
Ophthalmology. 118:2041–2049. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Campochiaro PA, Heier JS, Feiner L, Gray
S, Saroj N, Rundle AC, Murahashi WY and Rubio RG; BRAVO
Investigators, : Ranibizumab for macular edema following branch
retinal vein occlusion: Six-month primary end point results of a
phase III study. Ophthalmology. 117:1102–1112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Campochiaro PA, Sophie R, Pearlman J,
Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L and Patel A;
RETAIN Study Group, : Long-term outcomes in patients with retinal
vein occlusion treated with ranibizumab: The RETAIN study.
Ophthalmology. 121:209–219. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Glanville J, Patterson J, McCool R,
Ferreira A, Gairy K and Pearce I: Efficacy and safety of widely
used treatments for macular oedema secondary to retinal vein
occlusion: A systematic review. BMC Ophthalmol. 14:72014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kinge B, Stordahl PB, Forsaa V, Fossen K,
Haugstad M, Helgesen OH, Seland J and Stene-Johansen I: Efficacy of
ranibizumab in patients with macular edema secondary to central
retinal vein occlusion: Results from the sham-controlled ROCC
study. Am J Ophthalmol. 150:310–314. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Regnier SA, Larsen M, Bezlyak V and Allen
F: Comparative efficacy and safety of approved treatments for
macular oedema secondary to branch retinal vein occlusion: A
network meta-analysis. BMJ Open. 5:e0075272015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thom HH, Capkun G, Nixon RM and Ferreira
A: Indirect comparisons of ranibizumab and dexamethasone in macular
oedema secondary to retinal vein occlusion. BMC Med Res Methodol.
14:1402014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wolf-Schnurrbusch UE, Ghanem R,
Rothenbuehler SP, Enzmann V, Framme C and Wolf S: Predictors of
short-term visual outcome after anti-VEGF therapy of macular edema
due to central retinal vein occlusion. Invest Ophthalmol Vis Sci.
52:3334–3337. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Keane PA and Sadda SR: Predicting visual
outcomes for macular disease using optical coherence tomography.
Saudi J Ophthalmol. 25:145–158. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ota M, Tsujikawa A, Murakami T, Kita M,
Miyamoto K, Sakamoto A, Yamaike N and Yoshimura N: Association
between integrity of foveal photoreceptor layer and visual acuity
in branch retinal vein occlusion. Br J Ophthalmol. 91:1644–1649.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shin HJ, Chung H and Kim HC: Association
between integrity of foveal photoreceptor layer and visual outcome
in retinal vein occlusion. Acta Ophthalmol. 89:e35–e40. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jaissle GB, Szurman P, Feltgen N, Spitzer
B, Pielen A, Rehak M, Spital G, Heimann H and Meyer CH: Retinal
vein occlusion study group: Predictive factors for functional
improvement after intravitreal bevacizumab therapy for macular
edema due to branch retinal vein occlusion. Graefes Arch Clin Exp
Ophthalmol. 249:183–192. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bhisitkul RB, Campochiaro PA, Shapiro H
and Rubio RG: Predictive value in retinal vein occlusions of early
versus late or incomplete ranibizumab response defined by optical
coherence tomography. Ophthalmology. 120:1057–1063. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sakamoto A, Tsujikawa A, Ota M, Yamaike N,
Kotera Y, Miyamoto K, Kita M and Yoshimura N: Evaluation of
potential visual acuity in eyes with macular oedema secondary to
retinal vein occlusion. Clin Experiment Ophthalmol. 37:208–216.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Clarkson JG, Chuang E, Gass D, Pedroso M,
Cubillas T, Duria ES, Hess DJ, Rams I, Ball M, Gutierrez A, et al:
Evaluation of grid pattern photocoagulation for macular edema in
central vein occlusion. The central vein occlusion study group M
report. Ophthalmology. 102:1425–1433. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Battaglia Parodi M, Saviano S and Ravalico
G: Grid laser treatment in macular branch retinal vein occlusion.
Graefes Arch Clin Exp Ophthalmol. 237:1024–1027. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ip MS, Scott IU, Van Veldhuisen PC, Oden
NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK and
Gonzalez VH: A randomized trial comparing the efficacy and safety
of intravitreal triamcinolone with observation to treat vision loss
associated with macular edema secondary to central retinal vein
occlusion: The standard care vs corticosteroid for retinal vein
occlusion (SCORE) study report 5. Arch Ophthalmol. 127:1101–1114.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao L, Li B, Feng K, Han L, Ma Z and Liu
Y: Bevacizumab treatment for acute branch retinal vein occlusion
accompanied by subretinal hemorrhage. Curr Eye Res. 40:752–756.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ach T, Hoeh AE, Schaal KB, Scheuerle AF
and Dithmar S: Predictive factors for changes in macular edema in
intravitreal bevacizumab therapy of retinal vein occlusion. Graefes
Arch Clin Exp Ophthalmol. 248:155–159. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hoeh AE, Ruppenstein M, Ach T and Dithmar
S: OCT patterns of macular edema and response to bevacizumab
therapy in retinal vein occlusion. Graefes Arch Clin Exp
Ophthalmol. 248:1567–1572. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kang HM, Chung EJ, Kim YM and Koh HJ:
Spectral-domain optical coherence tomography (SD-OCT) patterns and
response to intravitreal bevacizumab therapy in macular edema
associated with branch retinal vein occlusion. Graefes Arch Clin
Exp Ophthalmol. 251:501–508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Oishi A, Hata M, Shimozono M, Mandai M,
Nishida A and Kurimoto Y: The significance of external limiting
membrane status for visual acuity in age-related macular
degeneration. Am J Ophthalmol. 150:27–32. 2010. View Article : Google Scholar : PubMed/NCBI
|
